<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
		>
<channel>
	<title>Comments on: Trends Update &#8212; IP Constituencies: Rotman Article Explores Canadian Biotech Collaborations with Developing Countries</title>
	<atom:link href="http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/feed/" rel="self" type="application/rss+xml" />
	<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/</link>
	<description>Biotechnology, Health and Business in Canada, the United States and Worldwide</description>
	<lastBuildDate>Sat, 10 Dec 2011 04:09:15 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
	<item>
		<title>By: Social Media for Biotechs: Building momentum toward critical mass &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-3/#comment-1576</link>
		<dc:creator><![CDATA[Social Media for Biotechs: Building momentum toward critical mass &#171; The RIC Blog]]></dc:creator>
		<pubDate>Mon, 19 Apr 2010 15:22:39 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1576</guid>
		<description><![CDATA[[...] April 19, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] April 19, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: 2010 Ontario Budget stands still on innovation &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-3/#comment-1509</link>
		<dc:creator><![CDATA[2010 Ontario Budget stands still on innovation &#171; The RIC Blog]]></dc:creator>
		<pubDate>Wed, 31 Mar 2010 10:58:52 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1509</guid>
		<description><![CDATA[[...] March 31, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] March 31, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Personalized Medicine: The limits of Genomic Analysis &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-2/#comment-1411</link>
		<dc:creator><![CDATA[Personalized Medicine: The limits of Genomic Analysis &#171; The RIC Blog]]></dc:creator>
		<pubDate>Tue, 23 Feb 2010 11:40:30 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1411</guid>
		<description><![CDATA[[...] February 23, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] February 23, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Should FDA Special Protocol Assessments be Public? &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-2/#comment-1392</link>
		<dc:creator><![CDATA[Should FDA Special Protocol Assessments be Public? &#171; The RIC Blog]]></dc:creator>
		<pubDate>Tue, 16 Feb 2010 10:57:56 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1392</guid>
		<description><![CDATA[[...] February 16, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] February 16, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Personalized Medicine: The case for diagnostics focuses on cost and effectiveness &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-2/#comment-1286</link>
		<dc:creator><![CDATA[Personalized Medicine: The case for diagnostics focuses on cost and effectiveness &#171; The RIC Blog]]></dc:creator>
		<pubDate>Fri, 22 Jan 2010 11:37:39 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1286</guid>
		<description><![CDATA[[...] January 22, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] January 22, 2010 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Top three reasons why Biotech Companies should use Social Media &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-2/#comment-1178</link>
		<dc:creator><![CDATA[Top three reasons why Biotech Companies should use Social Media &#171; The RIC Blog]]></dc:creator>
		<pubDate>Thu, 17 Dec 2009 11:28:02 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1178</guid>
		<description><![CDATA[[...] December 17, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] December 17, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Commercialization by Foundations a good thing &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-2/#comment-1135</link>
		<dc:creator><![CDATA[Commercialization by Foundations a good thing &#171; The RIC Blog]]></dc:creator>
		<pubDate>Fri, 04 Dec 2009 13:10:54 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1135</guid>
		<description><![CDATA[[...] December 4, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] December 4, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Electronic Medical Records: two approaches &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-1/#comment-1109</link>
		<dc:creator><![CDATA[Electronic Medical Records: two approaches &#171; The RIC Blog]]></dc:creator>
		<pubDate>Thu, 26 Nov 2009 11:00:16 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1109</guid>
		<description><![CDATA[[...] November 26, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] November 26, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Nobel and Gairdner winners discuss Biotech and Pharma’s pipeline problems &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-1/#comment-1084</link>
		<dc:creator><![CDATA[Nobel and Gairdner winners discuss Biotech and Pharma’s pipeline problems &#171; The RIC Blog]]></dc:creator>
		<pubDate>Mon, 16 Nov 2009 11:47:02 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1084</guid>
		<description><![CDATA[[...] November 16, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] November 16, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: India’s Glenmark Pharmaceuticals Sets an Example for Canadian Innovation &#171; The RIC Blog</title>
		<link>http://crossborderbiotech.ca/2009/09/13/trends-update-ip-constituencies-rotman-article-explores-canadian-biotech-collaborations-with-developing-countries/comment-page-1/#comment-1000</link>
		<dc:creator><![CDATA[India’s Glenmark Pharmaceuticals Sets an Example for Canadian Innovation &#171; The RIC Blog]]></dc:creator>
		<pubDate>Fri, 09 Oct 2009 11:17:21 +0000</pubDate>
		<guid isPermaLink="false">http://crossborderbiotech.ca/?p=3119#comment-1000</guid>
		<description><![CDATA[[...] October 9, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]]]></description>
		<content:encoded><![CDATA[<p>[...] October 9, 2009 by RIC    Re-posted from the Cross-Border Biotech Blog [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

